Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.
You're using version {0} of the web browser {1}. This means that the content or functionality of our website may be limited or unavailable. We recommend that you upgrade your browser to optimise your experience of our website.
Targeting the ILC2-related transcription factor RORalpha as a possible treatment strategy in allergy and asthma
| Reference number | 2014-05735 |
| Coordinator | Karolinska Institutet - Innovationskontoret |
| Funding from Vinnova | SEK 350 000 |
| Project duration | November 2014 - March 2015 |
| Status | Completed |
